Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Margaret K. Callahan(Cornell University), Jedd D. Wolchok(Cornell University), Shigehisa Kitano(The Cancer Institute Hospital), Maria Jure‐Kunkel(Genmab (United States)), Gregg Masters(Memorial Sloan Kettering Cancer Center), Shachi Vyas(University of Pittsburgh), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Neal Rosen(Memorial Sloan Kettering Cancer Center), Christine A. Pratilas(Johns Hopkins University), Jianda Yuan, Valerie Russell(Memorial Sloan Kettering Cancer Center), Ruth Ann Gordon(Memorial Sloan Kettering Cancer Center), Ashok Gupta, Taha Merghoub(Cornell University), Jessica Katz(Memorial Sloan Kettering Cancer Center), Charlotte E. Ariyan(Memorial Sloan Kettering Cancer Center)
Cited by 120
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k